Tag: Epilepsy

Drug Candidate, CQ-001 (cannabidiol “CBD” + IP formula), also demonstrated substantially reduced seizures at higher doses, with less CBD, compared to standard CBD.   TORONTO, ON / iCrowdNewswire / December 8, 2022 / CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the “Company” […]

DelveInsight’s Epilepsy pipeline report provides comprehensive insights into 70+ companies and 70+ pipeline drugs in the Epilepsy pipeline landscape. It also covers pipeline drug profiles, including clinical and non-clinical stage products, therapeutics by product type, stage, route of administration, and […]